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SUMMARY
We combined reverse and chemical genetics to identify targets and compounds modulating blood
vessel development. Through transcript profiling in mice, we identified 150 potentially druggable
microvessel-enriched gene products. Orthologs of 50 of these were knocked down in a reverse
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genetic screen in zebrafish, demonstrating that 16 were necessary for developmental angiogenesis.
In parallel, 1280 pharmacologically active compounds were screened in a human cell-based assay,
identifying 28 compounds selectively inhibiting endothelial sprouting. Several links were revealed
between the results of the reverse and chemical genetic screens, including the serine/threonine (S/
T) phosphatases ppp1ca, ppp1cc, and ppp4c and an inhibitor of this gene family; Endothall. Our
results suggest that the combination of reverse and chemical genetic screens, in vertebrates, is an
efficient strategy for the identification of drug targets and compounds that modulate complex
biological systems, such as angiogenesis.
INTRODUCTION
Blood vessels allow for the efficient transportation of cells, macromolecules, nutrients, and
oxygen to peripheral tissues, and for the removal of carbon dioxide and waste products.
Angiogenesis is the formation of new blood vessels from existing ones and is an essential
component of both physiological and pathological tissue growth (Adams and Alitalo, 2007).
Angiogenesis inhibitors have become important drugs in the treatment of solid tumors and
age-related macular degeneration (reviewed by Andreoli and Miller [2007] and Ellis and
Hicklin [2008]). Bevacizumab (Avastin), a monoclonal antibody that neutralizes vascular
endothelial growth factor A (VEGF-A), was the first FDA-approved therapy selectively
targeting angiogenesis (Ferrara et al., 2004). However, Bevacizumab and other angiogenesis
inhibitors have several drawbacks; they are only efficient in combination with cytotoxic
drugs, there are significant side effects, and tumors may use alternate pathways to evade the
effect of VEGF-A blockade (Casanovas et al., 2005; Eskens and Verweij, 2006; Ridgway et
al., 2006; Zhu et al., 2007). Thus, there is a need to identify additional angiogenesis targets
and develop improved antiangiogenic drugs. Several gene products that are potential drug
targets for antiangiogenic applications have been revealed by reverse and forward genetic
studies in mice and zebrafish (Adams and Alitalo, 2007; Cha and Weinstein, 2007) .
Additionally, chemical genetic screens with in vitro cellular assays or in vivo screens in
zebrafish have been employed to identify drugs and drug-like compounds that can modulate
angiogenesis (Chan et al., 2002; Kwon, 2006; Tran et al., 2007).
In order to identify genes, known drugs, and pharmacologically active compounds
previously not implicated in angiogenesis modulation, we tested the feasibility of running
parallel reverse genetic (RG) and chemical genetic (CG) screens, taking advantage of
several different vertebrate model systems. Our hypothesis was that functionally important
targets and pathways will be conserved between species, and will therefore be represented in
several different models. Thus, identification of overlapping gene products in the RG and
CG screens would serve to reduce the noise and possibly reflect drug targets and/or
pathways that are fundamental for angiogenesis.
We used transcript profiling in mice to identify 150 potentially druggable microvessel-
enriched gene products. Orthologs of 50 of these were identified and verified by using
Ensembl or the National Center for Biotechnology Information’s Homolo-Gene and were
knocked down in a RG screen in zebrafish, demonstrating that 16 were necessary for
developmental angiogenesis. In parallel, we screened 1280 pharmacologically active
compounds in a human cell-based assay, identifying 28 compounds selectively inhibiting
endothelial sprouting. The mouse provided us with a well-studied mammalian system with
close homology to humans. The zebrafish offers several advantages for RG screening of
angiogenesis-modulating genes, including its rapid development that can be followed non-
invasively over time. Lastly, as the goal is to develop compounds for human targets and
diseases, we used a human cell assay for the CG screen.
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Our results support the notion that the combination of RG and CG screens, in vertebrates, is
an efficient strategy for the identification of drug targets and compounds that modulate
complex biological systems, such as angiogenesis.
RESULTS
Reverse Genetic Screen for Novel Angiogenesis Targets
The first step when selecting genes for the RG screen was to identify genes expressed in the
vasculature, i.e., endothelial cells, pericytes, and/or smooth muscle cells. We reasoned that
genes with high or selective expression in these cell types would have an increased
likelihood of being required for angiogenesis. In addition, an enriched expression in the
vasculature could potentially make them specific angiogenesis targets with fewer side
effects. We identified vascular-enriched genes by mRNA expression profiling of isolated
vascular fragments as well as nonvascular cells from developing and adult mouse tissues.
We chose to use mice because vascular fragments can be isolated in sufficient quantities
directly from the tissue with minimal perturbation of gene expression, and close similarities
exist between the mouse and human genomes. Specifically, we searched for genes that were
(i) generally enriched in vascular fragments; (ii) expressed in a particular vascular bed; and/
or (iii) expressed preferentially in either developing or adult vasculature. The expression
profiling was performed by using custom cDNA arrays constructed from cDNA libraries
from vascular fragments. The array contained 12,554 EST clones, representing 5856 unique
genes, and was estimated to cover approximately half of the microvascular transcriptome.
Importantly, genes known to be expressed in the vasculature, such as the vascular
endothelial cadherin (ve-cadherin/cdh5) and endoglin, were overexpressed in vascular
preparations compared to nonvascular cells (Figure 1; see Figures S1 and S2 available
online).
Genes were selected for further analysis based on microvascular-enriched expression, as
determined by microarray experiments; the presence of signal peptides and/or a
transmembrane motif, according to Ensembl annotation; druggability, as predicted by Gene
Ontology annotation; and literature searches (Figure S3; Tables S1 and S2). In summary,
this resulted in the selection of 150 mouse genes. Through comparison with a reference set
of 58 genes with known selective expression in the vasculature (Wallgard et al., 2008), we
estimated that the selection process resulted in a more than 20-fold enrichment of genes with
a vascular expression (Supplemental Experimental Procedures).
To assess gene function in a semi-high-throughput fashion, we chose to knock down the
gene products in zebrafish, by injection of antisense morpholino oligonucleotides (MPOs).
This approach allowed for a rapid assessment of the requirements of these genes during
angiogenesis in a whole organism. First, zebrafish orthologs of the selected genes were
identified by using BLAST searches of zebrafish cDNA and genomic sequence databases. A
total of 62 zebrafish orthologs representing 50 mouse genes were identified with a sufficient
5′ UTR sequence to allow for the construction of suitable MPOs (Tables S2–S4). These 62
genes were knocked down in zebrafish embryos by microinjection of at least two different
MPOs for each gene into 1-cell zebrafish embryos. To control for nonspecific effects as a
result of MPO injection, two nonoverlapping MPOs were used for each gene. Dose-response
experiments were carried out for each MPO individually and in combination. In addition,
injection of a mixed-base MPO had no effect on vascular development, even at a high dose
(Figure 4). The zebrafish embryos were analyzed at 24 and 56 hr postfertilization (hpf) for
alterations in vascular development. Selection criteria in the primary screen comprised
visually detectable defective blood flow and/or reduced intersegmental vessel (ISV)
sprouting detected as reduced cdh5 staining in the vessels at 48–56 hpf. Knockdown
embryos exhibiting either of those changes were analyzed in MPO dose-response studies
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and analyzed in detail for cdh5 mRNA expression at 24 and 56 hpf by mRNA in situ
hybridization. The embryos were also subjected to microangiography by using fluorescent
dextran injection at 48–56 hpf. Heart beat was monitored to exclude heart dysfunction as an
explanation for reduced vascular perfusion. Sixteen genes exhibited significant dose-
dependent vascular defects in response to both injected MPOs (Table 1; Figure S4; Table
S5). For one of them, rab5c, vascular leakage was also detected as extravasation of
fluorescent dextran (Figure S4I). Interestingly, several phosphatases were identified in the
RG screen. Three of the 16 genes were S/T phospatases (ppp1ca, ppp1cc, and ppp4), and
one was a predicted tyrosine phosphatase (kiaa1274, mouse ortholog x99384).
We performed mRNA in situ hybridization on mouse embryo tissue to validate the gene
expression of the 16 genes identified in the RG screen. Four out of 16 genes were selectively
expressed in vascular cells: sat1, ppap2a, x99384, and fzd6 (Figures 2A-2D; Figure S5
[Visel et al., 2004]). The other 12 genes, including 3 S/T protein phosphatases, ppp1ca,
ppp1cc, and ppp4c, were overexpressed in vascular cells, but were also expressed in other
cell types (Figures 2E-2G, and data not shown).
Chemical Genetic Screen for Novel Angiogenesis Drugs and Targets
We screened 1280 well-characterized compounds from the List of Pharmacologically Active
Compounds (LOPAC1280) in a cellular angiogenesis assay (Korff and Augustin, 1998). We
chose this chemical library, as the compounds have partially, to extensively, characterized
targets. The assay evaluates the effect of compounds on angiogenic sprouting of human
umbilical vein endothelial cells (HUVECs), stimulated with VEGF-A in a three-dimensional
collagen type I matrix (Figures S6A-S6D). The effect was determined as percentages of the
positive VEGF-A control, which was set to 100%. In the primary screen, 90 inhibitory
compounds were identified via microscope observation by two independent observers.
These compounds were rescreened, and their inhibitory effects on sprouting were quantified.
To assess endothelial selectivity, the set of 90 compounds were subsequently assayed for
their effects on fibroblast scattering by using normal human dermal fibroblasts (NHDFs).
Twenty-eight compounds, known to interact with 69 targets, showed significant inhibition of
endothelial sprouting (<50% of VEGF-A-induced sprouting), yet left fibroblast scattering
relatively unaffected (>50% of NHDF control scattering) (Figure 3; Table S6).
As expected, the screen identified compounds already known to inhibit angiogenesis. For
example, among the 90 antiangiogenic compounds we found the tyrosine kinase inhibitor
SU5416, designed to selectively inhibit VEGFR2 (Fong et al., 1999), and shown by others
to be antiangiogenic in zebrafish (Chan et al., 2002). Furthermore, Nimesulide and β-
Lapachone were among the 28 selective compounds. Nimesulide is a highly selective
cyclooxygenase-2 inhibitor that belongs to a class of drugs known to inhibit angiogenesis
(Tsujii et al., 1998). β-Lapachone, a naphthoquinone compound derived from the bark of the
lapacho tree (Tabebuia avellanedae), has been shown to have both antitumor activity and
antiangiogenic properties (Kung et al., 2007).
Reverse and Chemical Genetic Screens Identify an Overlap of Pathways and Targets
In the sets of 16 genes and 28 compounds, we found several regulators of prostaglandin/
leukotriene synthesis, molecules known to affect angiogenesis (reviewed by Romano and
Claria [2003]). For example, in the RG screen, we identified ppap2a, which converts
phosphatidic acid to diacylglycerol. Diacylglycerol is, in turn, converted to arachidonic acid,
the precursor of both prostaglandins and leukotrienes. Among the 16 targets of the RG
screen was alox5ap, which converts arachidonic acid to hydroperoxyeicosatetraenoic acid
(HPETE), the immediate precursor of leukotriene A4. Furthermore, among the 28
compounds identified in the CG screen, we discovered two compounds inhibiting
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prostaglandin and leukotriene biosynthesis: Nimesulide, which inhibits the synthesis of
prostaglandin from arachidonic acid, and Budesonide, which suppresses the synthesis of
both prostaglandin and leukotrienes, via the glucocorticoid receptor (Figure S7).
In light of the identification of 3 S/T protein phosphatases in the RG screen, it was striking
that 1 of the 28 compounds, Endothall, is known to inhibit S/T protein phosphatases. There
are five known gene families of S/T protein phosphatases: PPP1, PPP2A, PPP3, PPP5, and
PPP7 (Cohen, 2004). Endothall inhibits members of the PPP1 and PPP2A families (Erdodi
et al., 1995), with PP1 being five times less sensitive than PP2A to Endothall (Li et al.,
1993). Out of the S/T protein phosphatases identified in the RG screen, ppp1ca and ppp1cc
belong to the PPP1 family, and ppp4c belongs to the PPP2A family (Cohen et al., 2005;
Cohen, 2004). Thus, three genes that were identified in the RG screen corresponded to two
of the gene families identified in the CG screen (Figure 1).
There were three other S/T phosphatase inhibitors present among the 1280 compounds
screened: the PPP1 and PPP2A family inhibitors Cantharidin and Cantharidic acid (both
structural analogs of Endothall), as well as Cyclosporin A (a PPP3-family inhibitor).
Cantharidin and Cantharidic acid were present among the 90 identified antiangiogenic
compounds. However, at the screening concentration used, these compounds also affected
fibroblast scattering, and were thus excluded in the process. Cyclosporin A had no effect on
angiogenic sprouting (data not shown), further suggesting specificity to the involvement of
PPP1 and PPP2A family members in angiogenesis.
Protein Phosphatases ppp1ca, ppp1cc, and ppp4c Affect Vascular Perfusion
We next focused on the S/T protein phosphatases that overlapped in the two screens. First,
we performed a dose-response titration of Endothall in the cellular angiogenesis assay. This
resulted in IC50 values for HUVECs and NHDFs of 0.25 μM and 1.2 μM, respectively, thus
indicating that endothelial cells are five-fold more sensitive to PPP1 and/or PPP2A
inhibition than NHFDs (Figures S6E and S6F). Second, to better characterize the effects
observed in the RG screen, we repeated the zebrafish knockdown experiments with ppp1ca,
ppp1cc, ppp4c, and control MPOs in a transgenic line of zebrafish expressing green
fluorescent protein in endothelial cells, Tg(fli1:egfp)y1. These transgenic embryos allowed
us to follow endothelial migration during embryonic vasculogenesis and angiogenesis.
Subsequent formation of patent perfused vessels was assessed by using microangiography at
48–50 hpf.
In all S/T protein phosphatase knockdowns, microangiography revealed defects in perfusion
(Figure 4; Table 2). The endothelial cells that form the axial vasculature migrated to the
midline, and sprouting from this location to form the ISVs appeared to be normal. However,
in the most severely affected embryos of ppp1cc knockdowns, the ISVs displayed excessive
branching, although the endothelial cells were able to migrate dorsally. This path-finding
phenotype is similar to the knockdowns of the neuropilins in zebrafish (Martyn and Schulte-
Merker, 2004). For knockdown of ppp1ca and ppp4c, incomplete perfusion was
accompanied by a dilated or enlarged vessel diameter (J.J.E., unpublished data). Based on
the phenotypes observed after gene knockdown, the protein phosphatases ppp1ca, ppp1cc,
and ppp4c may thus have roles during both endothelial guidance and tubulogenesis/
perfusion. The PPP1 and PPP2A gene families have many targets and have been implicated
in numerous cellular functions (reviewed by Cohen [2002, 2004] and Cohen et al. [2005]).
They are highly conserved and homologous, which suggests a high degree of functional
redundancy. However, the vascular defects in otherwise overtly normal S/T protein
phosphatase knockdown embryos indicate specific functions or particular sensitivity to
protein phosphatase-regulated signaling in the vasculature.
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Endothall Treatment of Zebrafish Phenocopies the Knockdowns of ppp1ca, ppp1cc, and
ppp4c
Next, we were interested to test whether treatment with Endothall, the S/T phosphatase
inhibitor identified in the chemical screen, would result in similar phenotypes as the
knockdowns of the S/T protein phosphatases. Zebrafish embryos were soaked in different
concentrations of Endothall, and treatment was initiated at the 20-somite stage (equivalent to
20 hpf). During this stage, the axial vessels in the trunk, the dorsal aortal, and the cardinal
vein form by vasculogenesis and begin tubulogenesis. Also, at the same time, the first wave
of angiogenesis from the dorsal aorta begins as endothelial cells migrate to form the ISVs.
Using a similar strategy as for the analysis of the knockdown phenotypes described above
(Figure 4), endothelial migration during formation of the ISVs was followed in the
Tg(fli1:egfp)y1 transgenic embryos, and the emergence of patent vessels was investigated by
using microangiography at 48–50 hpf. Similar to knockdowns of ppp1ca, ppp1cc, and ppp4,
Endothall treatment resulted in dose-dependent reduction of ISV perfusion without strongly
affecting endothelial migration (Figure 5).
DISCUSSION
To our knowledge, this is the first systematic study combining parallel RG and CG screens
in vertebrates. CG screens are powerful tools in research and drug discovery, but they are
hampered by the difficulty of identifying the targets of the effective compounds. In
invertebrates, it has been shown that a comparison between phenotypes resulting from RG
and compound screens in the same model system may reveal targets or pathways affected by
the compound. For example, in Drosophila, phenotypic comparison showed that γ-secretase
inhibitors target the NOTCH receptor, and in Caenorhabditis elegans, Ezetimibe was shown
to target the annexin2 pathway (Ross-Macdonald, 2005). Moreover, the use of systematic
RG and CG screening in Drosophila has linked new drug-like compounds to known
pathways that control specific biological processes, such as cytokinesis (Eggert et al., 2004).
However, from a drug development perspective, invertebrate model systems have
limitations both in the types of biological processes that may be assayed, and in their
relevance to human disease. For example, limitations are apparent when diseases that affect
the vascular system are considered. Many of the known signaling pathways in the vascular
system of vertebrates are not represented in invertebrates, nor are well-developed circulatory
systems. Our results suggest that parallel RG and CG screens can be used, not only in
invertebrates, but also in more complex, and for human disease, more relevant vertebrate
systems, to identify candidate targets/pathways hit by to compounds having an effect in
chemical screens. Larger screens and applications in other areas than angiogenesis are
clearly needed to validate whether the combination of RG and CG screens in vertebrates
commonly identify the same targets and processes, but our study does suggest that this may
very well be the case.
The task of identifying the overlap of the screens was simplified because the targets of the
compounds used in the CG screen have previously been partly characterized. This is not the
case when large libraries containing new chemical entities are tested. However, the fact that
Endothall phenocopied the knockdowns of ppp1ca, ppp1cc, and ppp4c, and that we
identified key components of the prostaglandin/leukotriene biosynthesis pathway in both
screens, suggest that detailed phenotypic comparison of RG and CG screens can reveal
which targets or pathways are also affected by novel chemical entities.
Obviously, an important question is whether the assays score for the same biological
process. In the CG screen, the readout is inhibition of endothelial sprouting, and in the RG
screen we screen for both angiogenesis and perfusion defects. In the CG screen, we
identified Endothall as a compound with inhibitory effects on endothelial sprouting.
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However, when we knock down the expression of its target genes, including ppp1ca,
ppp1cc, and ppp4cc, we primarily detect a defect in vascular perfusion, but not in
endothelial migration. We believe that the underlying mechanism triggering the different
outcomes might be the same, but depending on the specific assay or model, they will result
in different phenotypes. This has been observed before when studying the same gene in
different models. For example, the mouse knockout of vegfr2 results in early embryonic
lethality due to a halt in vasculogenesis and angiogenesis (Shalaby et al., 1995). However,
the knockdown of vegfr2 in zebrafish displays flow defects (Bahary et al., 2007).
Importantly, it is clear from both of these studies that vegfr2 has an important role in blood
vessel development. Needless to say, results from a screen must be interpreted carefully, and
more studies are required to confirm and extend the analysis in order to mechanistically
understand the results of these initial findings.
The LOPAC set of 1280 compounds contained 4 S/T protein phosphatase inhibitors in total.
Three PPP1 and PPP2A inhibitors, Cantharidin, Cantharidic acid, and Endothall, were
among the set of 90 antiangiogenic compounds identified. The fourth inhibitor was
Cyclosporin A, a PPP3-family inhibitor that was not identified by the screens, suggesting
that PPP1 and PPP2A, but not PPP3, have roles in vascular development. Cantharidin and
Cantharidic acid were excluded from the final hit list, not because they were not efficient
antiangiogenic compounds, but rather because they also had an inhibitory effect on
fibroblast scattering. Importantly, Cantharidin and Cantharidic acid are ~10-fold more
potent inhibitors of PPP1 and PPP2A than Endothall. Thus, at the screening concentration
used, any selective sensitivity of HUVECs (compared to NHDFs) to Cantharidin and
Cantharidic acid is likely masked by the potency of these compounds, enabling them to
affect NHDFs as well.
The PPP1/PPP2A inhibitor Endothall and its structural analogs are compounds with an
inherent and increasing toxicity in the following sequence: Endothall < Cantharidic acid <
Cantharidin (Li et al., 1993). In our experiments, in which zebrafish embryos were treated
with Endothall, the effective dose was close to the toxic dose. This finding is supported by
studies of Cantharidin in mice by others (Eldridge and Casida, 1995; Wang, 1989).
Nevertheless, there are several lines of evidence that suggest that members of the PPP1 and
PPP2 families have specific roles in vascular formation. First, morpholino knockdowns of
ppp1ca, ppp1cc, and ppp4 are selective, and each results in vascular defects in
morphologically overtly normal embryos (Figure 4; Figures S4K, S4L, and S4O). Second,
the IC50 titration of Endothall indicates that endothelial cells are more sensitive than
NHDFs. Third, the effect of Endothall on vascular perfusion in zebrafish was dose
dependent and effective at a lower than toxic dose. In summary, this argues for a primary
role of the PPP1 and PPP2A families of S/T phosphatases in proper vascular formation.
The fact that two independent screens identified S/T protein phosphatases from the PPP1
and PPP2A families suggests that these genes are critically involved in angiogenesis. Our
findings are strengthened by the fact that we arrive at the same targets from screening
approaches involving different species and models. Future studies will address the
mechanisms behind the effects of the PPP1 and PPP2A families of S/T phosphatases on
blood vessels. Potential mechanisms for the PPP1 family include modulation of vascular
permeability, cytoskeletal structure, and filopodia extension. PPP2A has been implicated in
endothelial migration (Hartel et al., 2007; Li et al., 2007; Shinoki et al., 1995; Young et al.,
2002). Moreover, Cantharidin, the 2, 3-dimethylanhydride of Endothall, has been shown to
enhance endothelial-mediated contraction of arteries and endothelial permeability (Knapp et
al., 1999, 2000). We thus note that the cell biological roles of the PPP1 and PPP2A families,
to a certain extent, overlap those of VEGF-A, and we are currently investigating the
relationship of these genes to the VEGF pathway (J.J.E., unpublished data). Another major
Kalén et al. Page 7













signaling pathway in vascular biology is TGF-β (reviewed by Gaengel et al. [2009]),
affecting many different steps in angiogenesis, including lumen formation (Oh et al., 2000).
It is therefore interesting that PP1α determines the duration of TGF-β signaling
(Valdimarsdottir et al., 2006). Furthermore, the PPP1 and PPP2A inhibitor Cantharidin,
historically extracted from the blister beetle, Mylabris phalerata, has been used in traditional
medicine as an antitumoral substance for thousands of years. When tested in the clinic,
Cantharidin was shown to have beneficial effects against primary hepatoma (Wang, 1989).
It will be important to determine the degree to which these effects on tumorigenesis are
attributable to the antiangiogenic properties of PPP1 and PPP2A inhibitors shown in this
study.
EXPERIMENTAL PROCEDURES
RNA Preparation and cDNA Library Construction
Isolation of mouse microvascular fragments by using Dynabeads (Dynal, Invitrogen) has
been described previously (Bondjers et al., 2006). In this study, microvascular fragments
were isolated from adult brain and liver and from embryonic (E16.5–18.5) brain, liver, and
skin from wild-type, Tie-1 knockout, PDGF-B knockout, and PDGF-Rβ knockout embryos.
Protocols were optimized by using Tie2LacZ mice, a knockin mouse in which the
endothelial cells can be stained with X-Gal. Using RNeasy mini kits (QIAGEN), 300 mg
vascular total RNA was isolated. The RNA was used to produce a standard oligodT-primed
cDNA library (Soares et al., 1994) (custom synthesis by Incyte). In addition, three
normalized libraries were generated from the standard library by using a modification of the
technique described by Soares et al. (1994), in which high-abundance transcripts were
suppressed to different degrees. In total, the four libraries comprised 16,000 cDNAs cloned
into the pBluescript vector and stored as bacterial clones. For descriptions of subsequent
sequence trimming and annotation, please see Supplemental Experimental Procedures.
Microarray Data Generation
For a description of the production of spotted cDNA microarrays (the Angio chip), please
see Supplemental Experimental Procedures.
Mouse microvascular fragments and the corresponding nonvascular tissue from embryonic
(E18.5) heart and skin, adult brain, and adult heart were prepared as previously described
(Bondjers et al., 2006). After the separate isolation of total RNA from these cell fractions,
the RNA was amplified for two rounds (Scheidl et al., 2002; Wang et al., 2000), in parallel
with Universal Mouse Reference RNA (Stratagene). Amplified sample RNA was labeled
with the fluorescent dye Cyanine-3 (Cy3) conjugated to UTP (Amersham-Pharmacia, now
GE Healthcare), and the Universal Mouse Reference was labeled with Cyanine-5 (Cy5)
conjugated to UTP. Cy3- and Cy5-labeled materials were simultaneously hybridized to the
Angio chip, by using the DIG Easy Hyb hybridization solution (Roche). Hybridizations
were performed in a water bath for 1.5 hr at 44°C, instantly followed by 15–20 hr at 40°C.
Hybridized microarrays were washed and thereafter scanned by using a dual laser scanner
(GenePix 4000B, Axon). Raw data were extracted by using ImaGene (BioDiscovery) and
were processed and normalized with the LOESS method by using the Bioconductor Limma
Package (version 2.9.11, www.bioconductor.org).
Mouse mRNA In Situ Hybridization
Nonradioactive mRNA in situ hybridization was performed on 14 mm thick sections with
digoxygenin-labeled RNA probes (Boehringer Ingelheim) visualized by alkaline
phosphatase-conjugated antidigoxygenin antibodies, as described previously (Bostrom et al.,
1996). Antisense and sense probes for the investigated genes were generated from the
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corresponding EST clones of the vascular cDNA libraries through restriction, followed by
transcription, with T7 and T3 RNA polymerases.
Zebrafish Experiments
Morpholino design and injection were carried out as described (Nasevicius and Ekker,
2000). For each gene, two nonoverlapping morpholinos were designed against the 5′UTR to
the first 25 bp of coding sequence and injected individually and together. When two
zebrafish orthologs were found that corresponded to one mouse gene, the overlapping
requirements of both genes during vascular development were tested in double knockdown
experiments. In situ hybridization with cdh5 was conducted as described (Larson et al.,
2004) with ~40 embryos that were coinjected with two morpholinos. Morpholino doses that
resulted in severe cell death were avoided (Ekker, 2000). To control for nonspecific effects
as a result of MPO injection, two nonoverlapping MPOs were used for each gene, and dose-
response curves were carried out for each MPO individually and in combination. Forty-six
of the genes targeted with MPOs had little or no effect on vascular development, suggesting
specificity for the 16 genes we identified as being required for vascular development. In
addition, injection of a mixed-base MPO had no effect on vascular development, even at a
high dose. Microangiography was performed by using FITC or rhodamine-dextran injection
into the sinus venosus (Nasevicius and Ekker, 2000). Both in situ hybridization and
microangiography experiments were scored by examining endothelial migration and
circulation in the intersegemental vessels.
For injection experiments, 3μl of a solution containing Endothall in 0.5% DMSO was
injected directly into the yolk of dechorionated 20-somite-stage Tg(fli1:egfp)y1 embryos.
For bathing experiments, dechorionated embryos were incubated with different
concentrations of Endothall in fish water containing 0.5% DMSO. Embryos were raised to
48–50 hpf in plastic petridishes with a 1% agarose pad. Microangiography was performed
by injection of 2–5 μl 5 mg/ml rhodamine-dextran (1,000,000 MW, Invitrogen).
Fluorescence was observed on a Zeiss Discovery dissection scope. Vascular defects were
categorized as normal, low (i.e., <30% absence of intersegmental vessel staining or FITC-
dextran signal), Medium (i.e., 31%–70% defective intersegmental vessel staining/signal), or
high (i.e., >70% defective intersegmental vessel staining/signal).
Chemical Genetic Screen
LOPAC1280 (Library of Pharmacologically Active Compounds) is a collection of chemical
compounds that contains marketed drugs, failed development candidates, and “gold
standards” that have well-characterized activities (Sigma-Aldrich, Inc.). The LOPAC
compounds were tested at a concentration of 10 μM to evaluate their potential to inhibit
VEGF-stimulated sprouting of endothelial cells clustered in a three-dimensional gel. Test
substances were stored at −20°C and thawed prior to use. Test substances (10 mM) were
diluted to a 10-fold concentrated working solution (100 μM) in endothelial cell basal
medium with 25 ng VEGF/100 μl for the stimulation of HUVEC sprouting or without
VEGF for assaying fibroblasts.
Compounds were tested as described by Korff and Augustin (1999). In brief, spheroids were
prepared by pipetting 500 cells (HUVEC, PromoCell, Heidelberg, Germany) or fibroblasts
(NHDF, PromoCell) in a hanging drop on plastic dishes to allow for overnight spheroidal
aggregation. Spheroids were harvested, and 50 spheroids were seeded in a solution of 900 μl
methocel-collagen and pipetted into individual wells of a 24-well plate to allow collagen gel
polymerization. Samples were added after 30 min by pipetting 100 μl of a 10-fold
concentrated working dilution of the test substances on top of the gel. Plates were incubated
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at 37°C for 24 hr. Dishes were fixed at the end of the experimental incubation period by the
addition of 1 ml 10% paraformaldehyde.
In the primary screen, the sprouting intensity of endothelial cells was assayed
microscopically by two independent investigators. In a rescreen, the sprouting intensity of
endothelial cells and fibroblasts was quantified by a semiautomated image-analysis system.
The cumulative sprout length per spheroid was determined by using an Olympus IX50
inverted microscope and the digital imaging software analySIS (Soft Imaging System,
Münster, Germany). The mean of the cumulative sprout length of ten randomly selected
spheroids in each well was analyzed and used as an individual data point. The reductions in
angiogenic sprout length were expressed as percentages of the positive VEGF-A control,
which was set to index 100. For each plate, baseline control sprouting was measured and
subtracted from the measured value of sprout length to ensure valid measurement of VEGF-
A-induced sprouting. Thus, the reduction of sprout length (percentage of VEGF-A-induced
control) may occasionally give values below zero. The inhibitors were classified according
to the following: category 1, inhibition of VEGF-induced HUVEC sprouting (<80% of
control sprouting), with a limited effect on fibroblast scattering (>50% of control); category
2, HUVEC sprouting < 50% of control, and fibroblast scattering > 50% of control; category
3, HUVEC sprouting < 50% of control, and fibroblast scattering < 50%; category 4,
HUVEC sprouting > 50% of control. A cutoff was set at category 2; thus, only compounds
in categories 1 and 2 were included in the list of the 28 selective antiangiogenic compounds.
The HUVEC spheroids display minor sprouting activity without the presence of VEGF-A
(Figure 4A), which represents the baseline.
Statistical Analysis
At least three biological replicates were used for every cell fraction (e.g., adult brain EC)
tested. RNA was isolated from all cell fractions, and each sample was subsequently used for
one individual microarray hybridization. The average expression value was calculated for
each gene in every sample group (e.g., adult heart EC or embryonic heart EC). The fold
change of each gene between the two sample groups was calculated as the ratio between the
two averages. To assess the significance of differential expression, a Student’s t test was
performed on each gene to obtain the raw p value (two-sided, equal variance) (Cui and
Churchill, 2003). Multiple test correction of raw p values was done by using the false
discovery rate method (Hochberg, 1995). The calculation was performed by using the stats
package in R (version 2.4.1, www.r-project.org). Genes with a raw p value ≤ 0.05 and a log2
ratio ≥ 0.3 or ≤ −0.3 were considered as significantly regulated.
For the chemical genetic screen, the average sprout length was determined and the
confidence interval was calculated at the α level of 0.05. All selected compounds inhibited
sprouting by more than 50% of control when using HUVEC spheroids (p < 0.05), but less
than 50% of control when using NHDF spheroids (p < 0.05).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Inhibition of angiogenesis is an important mode of action for several oncology drugs on
the market, but there is still a need to find new drugs to obtain greater efficacy and fewer
side effects. We show that parallel reverse genetic (RG) and chemical genetic (CG)
screens complement each other and facilitate target identification in angiogenesis.
Thereby, we identify 16 putative drug targets and 28 pharmacologically active
compounds, targeting 69 gene products, all with angiogenesis-regulating properties.
Importantly, we identify an overlapping set of targets and pathways from the two
screening approaches. To our knowledge, this is the first report describing the use of
parallel RG and CG in vertebrates to identify and validate drug targets and pathways.
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Figure 1. Experimental Overview of the Parallel Reverse and Chemical Genetic Screens
(A) The reverse genetic (RG) screen comprised 5856 genes derived from cDNA libraries,
constructed from pooled mouse vascular fragments isolated in vivo. Vascular and
corresponding nonvascular samples from various tissues and stages were isolated and
underwent RNA extraction, amplification, and labeling. After mRNA expression profiling,
150 mouse genes were selected for functional validation. Fifty mouse genes had suitable
zebrafish orthologs, and their functional importance in angiogenesis was evaluated by
morpholino-mediated knockdown in zebrafish embryos. Sixteen of the 50 knockdowns
resulted in vascular defects.
(B) In a separate chemical genetic (CG) screen, 1280 compounds were screened in a human
cellular angiogenesis assay. Ninety compounds inhibited in vitro angiogenesis, and 28 of
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these, targeting 69 proteins, did not affect fibroblast scattering. At the intersection of the two
screens, three genes encoding members of the PPP1 and PPP2 families of S/T phophatases
were identified as angiogenesis targets.
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Figure 2. Validation of Vascular Expression of Gene Products Identified in the Reverse Genetic
Screen
(A–G) Gene expression determined by nonradioactive mRNA in situ hybridization (blue) on
mouse tissues. (A) sat1 expression was restricted to the microvasculature in the heart at
embryonic day (E) 17.5. (B) Expression of sat1 in the vasculature of kidney glomeruli (G) at
E17.5. Arrows indicates afferent and efferent arterioles. (C and D) At E17.5, ppap2a was
mainly expressed in large vessels, here exemplified by two vessels in skeletal muscle
(skeletal m.) and a vein (vein). (E–G) The S/T protein phosphatases ppp1ca, ppp1cc, and
ppp4c were all expressed in the vasculature as well as in other cell types. (E) Vascular
ppp1ca staining in the brain at E17.5 (arrowheads). (F) Vascular expression of ppp1cc in the
brain at E14.5 (arrowheads). (G) Vascular expression of ppp4c in skeletal muscle at E17.5
(arrowheads). Scale bars represent 100 μm.
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Figure 3. Twenty-Eight Compounds Inhibit VEGF-A-Induced HUVEC Sprouting Angiogenesis
VEGF-A-driven HUVEC angiogenesis was quantified as the average cumulative sprout
length (black bars). The VEGF-A-driven sprouting was set to 100%, and the basal sprouting
in the absence of VEGF-A was set to 0%. The red line is a reference line for the basal
HUVEC sprouting. Scattering of clustered NHDFs in collagen gels in the presence of basal
medium was set to 100% (gray bars). Twenty-eight compounds from the LOPAC library
inhibited sprouting at > 50% (black bars) and NHDF scattering at < 50% (gray bars).
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Figure 4. Knockdown of ppp1ca, ppp1cc, and ppp4c Results in Defects in Endothelial Path
Finding and Tubulogenesis
(A–L) Images are all lateral views of the trunk vasculature at 48–50 hpf. (A–C) Control
embryo injected with a mixed-base morpholino. (D–L) Embryos injected with morpholinos
against (D–F) ppp1ca, (G–I) ppp1cc, and (J–L) ppp4c. Endothelial cells (shown with green
fluorescence in [A], [D], [G], and [J]) were identified by using the Tg(fli1:egfp)y1 line.
Dorsal aortas are marked with arrowheads, examples of perfused ISVs are marked with
arrows, and examples of nonperfused ISVs are labeled with asterisks. (D and J) The ppp1ca
and ppp4c knockdowns resulted in enlarged ISVs, whereas (G) knockdown of ppp1cc
resulted in excessive branching of the ISVs. (B) At 48–50 hpf, circulation as observed by
microangiography was observed in control injected embryos (mixed-base MPO) in the
dorsal aorta, cardinal vein, and ISVs. (E and K) Rhodamine-dextran dye (red) often entered
the ventral aspect of the ISVs in the ppp1ca and ppp4c knockdowns (a more severely
affected embryo is shown for ppp4c), but a circulatory loop was not established. (H) The
ppp1cc knockdown embryos showed either an absence of circulation or thin vessels with
reduced circulation. (C, F, I, and L) Merged images of the embryos shown in the previous
two panels.
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Figure 5. Treatment of Embryos with Endothall Results in Defects in Tubulogenesis
(A, D, and G) Endothelial cells in the trunk were analyzed for defects in migration in the
Tgfli1: (egfp)y1 line (green fluorescence) at 48–50 hpf. (B, E, and H) Analysis of circulation
defects by using microangiography (rhodamine-dextran imaging, red) at 48–50 hpf. (A–I)
are lateral views of the trunk. (A–C) Treatment with either carrier (DMSO control) or (D–I)
Endothall did not alter endothelial migration (see Tgfli1:egfp)y1 in [A], [D], and [G]). (B, E,
and H) Microangiography revealed defects is circulation consistent with defects in
tubulogenesis. Two classes of affected embryos are shown. In weakly affected embryos (low
effect), some of the ISVs would fail to circulate rhodamine-dextran. In more severely
affected embryos (high effect), most of the ISVs failed to transfer dye. (C, F, and I) Merged
images of the previous two panels. Dorsal aortas are marked with arrowheads, examples of
perfused ISVs are marked with arrows, and examples of non-perfused ISVs are labeled with
asterisks. (J) Dose response to bathing embryos in Endothall. Embryos were scored based on
circulation in the axial vessels and the ISVs as in Table 2. Vascular collapse was observed
with the highest concentration of Endothall.
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